Was it a double-blind clinical trial? If not, then it is 'anecdotal' by the EFF-DA's standard applied to leronlimab. How did leronlimab perform 'anecdotally'? Much better than 30% with the absolute worst of the worst with multiple comorbidities....is what I recall. So yeah, what were you saying?